EVENITY ™ (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine

EVENITY Followed by Alendronate Reduced the Incidence of New Vertebral, Clinical, Non-Vertebral and Hip Fractures Compared to Alendronate Alone Additional Details on Observed Cardiovascular Safety Signal Provided THOUSAND OAKS, Calif. and BRUSSELS, Sept. 11, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced detailed results from the Phase 3 ARCH study showing that 12 months of EVENITY™* (romosozumab) followed by alendronate was superior in reducing new vertebral, clinical, non-vertebral and hip fracture risk ...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news